In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Myobacterium tuberculosis

Annals of Saudi Medicine

Volumn 25, Issue 5, 2005, Pages 409-412

  Akcali, Sinem ^a,c   Surucuoglu, Suheyla ^a   Cicek, Candan ^b   Ozbakkaloglu, Beril ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DILUTION; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; IN VITRO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SAMPLING; STANDARD; TUBERCULOSIS;

EID: 27944458875     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2005.409     Document Type: Article

References (24)

1. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimic Agents Chemother. 1989;33(1):1-5.
2. Garcia-Rodriguez JA, Garcia ACG. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother. 1993;32(6):797-808.
3. Gelber RH, Iranmanesh A, Murray L, Siu P, Tsang M. Activities of various quinolone antibiotics against Mycobacterium leprae infected mice. Antimic Agents Chemother. 1992;36(11):2544-2547.
4. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997;25(5):1213-1221.
5. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities. Antimicrob Agents Chemother. 1985;28(5):716-721.
6. Onodera Y, Tanaka M, Sato K. Inhibitory activitiy of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimic Chemother. 2001;47(4):477-450.
7. Kent PT, Kubica GP. Public Health Mycobacteriology, A Guide for the Level III Laboratory. Atlanta: Centers for Disease Control, 1985.
8. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/2003.320-WHO/CDS/CSR/RMD/2003.3:9-11.
9. Kartaloglu Z, Bozkanat E, Ozturkeri H, Okutan O, Ilvan A. Primary antituberculosis drug resistance at Turkish Military Chest Diseases Hospital in Istanbul. Medical Principles and Practise. 2002;11(4):202-205.
10. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis morbidity and mortality of a worldwide epidemic. J Am Med Assoc. 1995;273(3):220-226.
11. Snider DE, La Montane JR. The neglected global tuberculosis problem: A report of the 1992 World Congress of Tuberculosis. J Infect Dis. 1994;169(6):1189-1196.
12. Joint Tuberculosis Committee of the British Thoracic Surgary. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations. Thorax. 1998;53(7):536-548.
13. Guidelines for the managements of drug resistance tuberculosis. WHO/TB/96.210 (rev 1) 1997:1-47.
14. Hooper DC. Quinolone mode of action. Drugs. 1995;49, Suppl. 2:10-15.
15. Yew WW, Chau CH. Drug resistant tuberculosis in the 1990s. Eur Respir J. 1995;8(7):1184-1192.
16. Grassi C, Peona V. New drugs for tuberculosis. Eur Respir J Suppl. 1995;20:714-718.
17. Tomioka H. Prospects for development of new antimycobacterial drugs. J Infect Chemother. 2000;6(1):8-20.
18. Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2001;17(3):229-231.
19. Gross WM, Bonato DA, Vadney FS, Campbell S. In vitro activity of ciprofloxacin in multiple drug resistant strains of Mycobacterium tuberculosis: 1985-1992. Abstract. 93rd General Meeting of American Society on Microbiology 1993;abstr U-26:173.
20. LaBombardi VJ, Cataldo Caputzal L. Ciprofloxacin susceptibility testing by MIC and disc elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 1993;37(7):1556-1557.
21. Vacher S, Pellegrin JL, Leblanc F, Fourche J, Maugein J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother. 1999;44(5):647-652.
22. Rastogi N, Labrousse V, Goh SK. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Current Microbiol. 1996;33(3):167-175.
23. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1997;40(6):885-888.
24. Van Caekenberghe D. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. J Antimicrob Chemother. 1990;26(3):381-386.